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Summary 
A recently described splice variant of CD44 expressed in metastasizing cell lines of rat tumors, 
has been shown to confer metastatic potential to nonmetastasizing  rat pancreatic carcinoma and 
sarcoma cell lines. Using antibodies raised against a bacterial fusion protein encoded by variant 
CD44  sequences, we have explored the expression of variant CD44 glycoproteins  on human 
lymphoid cells and tissues and on non-Hodgkin's lymphomas.  Normal lymphohematopoietic 
cells express barely detectable low levels of variant CD44 glycoproteins, whereas T lymphocytes, 
upon activation by mitogen or antigen, transiently upregulate expression of specific  CD44 variant 
glycoproteins. The reaction pattern of various antibodies indicates that these CD44 variants contain 
the domain encoded by exon v6, which is part of the variant that in the rat confers metastatic 
capability. It is interesting  that overexpression of v6 was also found in several aggressive, but 
not low-grade,  non-Hodgkin's lymphomas. 
T 
umor metastasis is the principle cause of death for cancer 
patients.  A subset of parental tumor cells acquire these 
metastatic properties, presumably through a series of genetic 
alterations (1, 2). During the metastatic process, tumor cells 
detach from the primary tumor, migrate into the extracel- 
lular  matrix  (ECM)  2 and  invade  adjacent  structures  in- 
cluding blood and lymph vessels. Via lymph or blood, the 
tumor cells are subsequently transported to sites of metastatic 
outgrowth where they engage endothelium and the ECM. 
This process of tumor dissemination  bears resemblance to 
that of lymphocyte trafficking. Both involve highly mobile 
cells, cellular interactions with and migration via ECM and 
endothelium, and cellular transport via blood and/or lymph. 
Moreover, cell adhesion receptors are believed to be critically 
important in both processes. 
CD44, a heterogenous family of molecules with putative 
functions in cell-cell and cell-matrix adhesion, has recently 
I The first three  authors  contributed equally to this  paper. 
2  Abbreviations used in this  paper: ECM, extracellular matrix; NHL, non- 
Hodgkiffs  lymphoma; TCGF, T cell growth factor; WF, International 
Working Formulation. 
been linked to tumor dissemination  in several  systems  including 
human non-Hodgkin's lymphomas (NHL) (3-6), melanomas 
(7), and rat adenocarcinomas (8). In the rat system, highly 
metastatic pancreatic and mammary  carcinoma cell lines were 
found to express splice variants of the CD44 glycoprotein 
(8). These variants differ from the standard CD44 molecule 
in that they contain additional peptide domains inserted into 
the extracellular portion of the transmembrane protein (8, 
9). Some of these variant CD44 proteins have been shown 
to be causally involved in tumor metastasis formation. Coin- 
jection of variant-specific mAb with the metastasizing cells 
led to retardation  or even complete blockage of metastatic 
spread in vivo (10). Moreover, ovcrexpression  of the metastasis- 
specific CD44 variants in nonmetastasizing  tumor cell lines 
led to lymphogenic metastatic spread (8). The major CD44 
isoform  on lymphocytes is the smallest standard molecule 
(CD44s). In the rat, lymphocyte activation increases the fre- 
quency of a (v6 exon containing)  larger isoform which ap- 
pears to be important for the immune response (11). Splice 
variants containing v6 are also expressed on several normal 
human epithelia and on carcinoma lines from lung, breast, 
and colon (9, 12). Such variants are also found in colorectal 
carcinomas and their metastases (12). 
The  similarity  between tumor spread and lymphocyte 
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processes, raises the question whether CD44 splice variants 
expressed by lymphocytes might be involved in the migra- 
tion of normal and malignant lymphocytes. In the present 
study, we have therefore explored the expression of CD44 
variant  glycoproteins on  normal  human  lymphocytes and 
malignant lymphomas.  Whereas  expression of CD44 vari- 
ants on normal lymphohematopoietic cells and tissues is very 
low, T cell activation by mitogen or antigen leads to a strong 
transient upregulation of CD44 variant expression. It is in- 
teresting that CD44 variants, particularly homologues of vari- 
ants that confer metastatic behavior in the rat,  are also ex- 
pressed in  aggressive malignant  lymphomas. 
Materials and Methods 
Cloning ofpGEX Fusion Proteins.  The whole variant region of 
the HPKII type CD44v (9, and see Fig. 1) was cloned from human 
keratinocyte cDNA via PCR amplification.  The two PCR primers 
5'-CAGGCTC,  GGAGCCAAATGAAGAAAATC--Y, positions 25-52, 
and  5'-TGATAAGGAACGATTGACATTAGAGTTGGA-Y,  posi- 
tions 1013-984 of the LCLC97 variant region as described in Hof- 
mann et al. (9), included an EcoRI recognition site, which was 
used to clone the PCR product directly into the pGEX-2T vector 
(13). The resulting construct (pGEX CD44v HPKII, v3-vl0) codes 
for a fusion protein protein of ",70 kD. 
To obtain subclones of the variant region that could later be used 
for affinity purification or Western blot analysis, DI (v3), DII/III 
(v5, v6), and Dill (v6, v7) comprising fragments (see Fig. 1) were 
cloned using appropriate restriction sites. Fusion protein DI con- 
tains the CD44 sequence described by Stamenkovic et al. (14) from 
position 744 to position 142 of variant CD44 described  by Hof- 
mann et al. (9), fusion protein DII/III contains the variant sequence 
from position 290 to 460, and fusion protein Dill the variant se- 
quence from position 378 to 638 (9). The DI and Dill comprising 
fragments were cloned into the pGEX vector system, and the DII/III 
fragment was cloned into the pATH-vector (15). 
Development of Polyclonal and Monoclonal Abs.  To obtain poly- 
clonal Abs against variant CD44, New Zealand White rabbits were 
immunized according to standard procedures.  In brief, 200/~g of 
affinity-purified fusion protein derived from pGEX CD44v HPKII 
(v3-10) was injected subcutaneously together with 400/~1 Freund's 
incomplete adjuvant four times within 9 wk. To remove Abs directed 
against  the glutathione transferase part of the fusion protein, the 
pGEX-2T glutathione transferase fragment was coupled to CNBr- 
activated Sepharose 4B (Pharmacia  LKB Biotechnology, Uppsala, 
Sweden).  The serum was applied  three consecutive times to the 
column, the flow-through was collected and loaded onto affinity 
columns to which CD44v HPKII (v3-10) was coupled. Specific 
Abs  were eluted with  100 mM glycine pH 2.5. 
To obtain mAb, female BALB/c mice were immunized with the 
affinity-purified fusion protein derived from pGEX CD44v HPKII 
(exons v3-10) described  above. Spleen cells of an animal  with a 
high Ab titer were fused to P3X63Ag8.653 myeloma cells using 
polyethylene glycol 4000; hybridomas were selected in HAT medium 
(16, 17). Determination of serum Ab titers and screening of hy- 
bridomas were performed by ELISA. Briefly, the assay plates were 
coated with the fusion protein, incubated with serial dilutions of 
serum samples of hybridoma supernatants, and specific Abs were 
detected with peroxidase-coupled Abs to mouse Ig. Hybridomas 
reactive with glutathione transferase were eliminated. The remaining 
Abs were further characterized in ELISA using fusion proteins of 
the variable domains DI (exon v3), DII/III (exons v5, v6), and 
Dill (exons v6, v7), respectively. The reactivity of the Abs with 
normal human  skin keratinocytes was  determined by immuno- 
histochemistry. For detection of standard CD44, we used mAb 
NKI-P1 (18). 
Western Blot Analysis.  Bacterial fusion proteins were taken up 
in gel sample buffer, boiled, and resolved on 10% SDS polyacryl- 
amide (19). Proteins were transferred to polyvinylidene difluoride 
membranes (Millipore GmbH, Eschborn, Germany) using a trans- 
blot apparatus (BioRad Laboratories, Cambridge, MA). Nonspecific 
interactions were blocked with PBS containing 10% dry milk. Sub- 
sequently, the membranes were incubated at room temperature with 
the Abs, followed by alkaline phosphatase-conjugated goat anti- 
rabbit IgG (Amersham International, Amersham, Bucks, UK), for 
1 h each. After each individual Ab incubation, the membranes were 
washed with PBS containing 0.3% Tween 20 (Sigma Immunochem- 
icals, St. Louis, MO). Signals were developed with the enhanced 
chemoluminescent system  (Amersham International). 
Tissues.  Normal and pathological tissues  were selected from 
the files of the Department of Pathology, Academic Medical Center, 
University of Amsterdam, and tested for expression of CD44 and 
variant CD44, employing the mono- and polyclonal Abs described 
above. All normal tissues were obtained as a corollary of standard 
surgical procedures. NHL were classified according to the Interna- 
tional Working Formulation (WF) (20). By their expression of T 
and B lineage  antigens they were divided into T  lineage  and B 
lineage. 
Immunohistochemistry.  Immunoperoxidase  staining  was  per- 
formed as described previously (12). In brief, cryostat sections were 
fixed in acetone for 10 min, washed in PBS, and preincubated with 
normal goat serum (10% in PBS). After preincubation, the sec- 
tions were incubated with the primary Ab for 1 h. Before incubating 
with the secondary biotinylated Ab for 30 rain (anti-mouse and 
anti-rabbit  F(ab)2; Dako Corp.,  Carpinteria,  CA),  endogenous 
peroxidases were blocked with 0.3% H202 in methanol. All Abs 
were titrated to give optimal staining results. For detection, a strep- 
tavidin-biotin-peroxidase complex (Dako Corp.) was used.  After 
incubation for 30 min, the sections were incubated in 3,3-amino- 
9-ethyl carbazole (Sigma  Immunochemicals) for 10-20 min. 
Cell Isolation.  PBMC  from normal donors were isolated  by 
Ficoll-Isopaque density gradient centrifugation. RBCs were taken 
from  the  Ficoll  pellet  and  washed  extensively in  RPMI  1640 
medium. Granulocytes were isolated from the Ficoll pellet by two 
rounds of R.BC lysis with hypotonic ammonium chloride. PBMC 
were further purified in a lymphocyte (PBL) and monocyte frac- 
tion by monocyte adherence on plastic petri dishes (Falcon Plastics, 
Oxnard, CA) for I h at 37~  The monocytes were harvested with 
a rubber policeman. Purity of PBLs, monocytes, and granulocytes 
was >95%  as determined by FACS  |  analysis (Becton Dickinson 
& Co., Mountain View, CA) for CD45, CD14, and CD15 expres- 
sion. For isolation of tonsil lymphocytes, freshly obtained tonsillar 
tissue was dissected free from surface epithelium and minced with 
scissors. Mononuclear cells were obtained by Ficoll-Isopaque  den- 
sity gradient centrifugation and monocytes were depleted by ad- 
herence on plastic  petri dishes. 
Cell Lines and Cell Cultures.  The cell lines used were: CEM, 
HSB-2, and Jurkat, T lymphoblastoid cell lines/T-ALLs; JVM-2, 
B-PLL; U937,  myelomonocytic line;  and HaCat,  spontaneously 
immortalized keratinocytes.  T  cells were activated  by culturing 
PBMC in the presence  of PMA (10 ng/ml),  with the anti-CD3 
mAb OKT3 (0.01%; Ortho Diagnostic Systems Inc., Raritan, NJ) 
and 5% T cell growth factor (TCGF), or with the anti-CD3 mAb 
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lands Red  Cross Blood Transfusion Service, Amsterdam,  The 
Netherlands), immobilized  on plastic (ascites 1:1000, coated at 4~ 
TCGF was produced as previously described (21). 
Lymphoid cell lines and T cells were cultured in RPMI  1640 
medium with 25 mM Hepes buffer (Gibco, Grand Island, NY), 
whereas HaCat was grown in DMEM (Gibco). All media were 
supplemented with 1 mM glutamine, 10% (vol/vol)  heat-inactivated 
FCS (Hyclone Laboratories Inc., Logan, UT), 100 U/ml natrium 
penicillin G (Gist Brocades  NV, Delft, The Netherlands), and 100 
U/ml streptomycin sulphate (Pharmachemie BV, Haarlem, The 
Netherlands). 
The influenza-specific  T cell clone K61-20 has been described 
elsewhere (22). 
Immunofluorescence.  Cells  were sequentially incubated (in PBS 
containing 1% BSA and 0.02%  sodium azide) with appropriate 
dilutions of the different antibodies and FITC-conjugated rabbit 
anti-mouse Ig (Dakopatts, Glostrop,  Denmark) or FITC-conjugated 
swine anti-Rabbit Ig (Dakopatts) for 30 min at 0~  For assaying 
the expression of  CD44 variants on anti-CD3 (IgG2a subclass)-acti- 
vated T cells, FITC-conjugated goat anti-mouse IgG1 subclass- 
specific Ig (Nordic Immunology, Tilburg, The Netherlands) was 
used. Fluorescence  was measured by a FACScan  |  flow cytometer 
(Becton Dickinson & Co.). 
Cell Proliferation.  T  cell proliferation was measured using a 
[3H]thymidine  incorporation assay. Anti-CD3-stimulated  T ceils 
were plated in 96-well flatbottomed tissue culture plates (Costar, 
Cambridge, MA) at 10  s cells per well, and cultured for 1-7 d in 
RPMI 1640 with Hepes and 10% FCS. During the last 4 h of 
the assay, the culture was pulsed with 0.5/zCi [methyl-3H]thymi  - 
dine (87 Ci/mmol; Amersham International). Results are expressed 
as the arithmetic mean cpm of triplicate cultures. 
RNA-PCR.  50-100 x  106 cells were harvested, pelleted, and 
dissolved in chaeotropic lysis buffer (3 M LiC1, 6 M Urea) and 
homogenized for 2.5 min at 0~  in a mixer (Omni International, 
Waterbury, CT) equipped with micro set-up at position 5.5. The 
homogenate  was allowed  to settle  overnight  at 0~  and subsequently 
the RNA was pelleted for 30 min at 25,000 rpm in a rotor (model 
SW60Ti; Beckman Instruments Inc., Fullerton, CA). The RNA 
pellet was dissolved in TES buffer (100 mM NaC1, 50 mM Tris- 
HC1, pH 7.4, 5 mM EDTA) containing 1% SDS and 2 mg/ml 
proteinase K (Boehringer Mannheim GmbH Biochemica, Mann- 
heim, Germany) and incubated for 30 min at 37~  After phenol- 
chloroform extraction, the RNA was precipitated twice in ethanol 
and stored at  -80~  in 70% ethanol until needed. RNA-PCR 
was performed on 1-/zg aliquots of total RNA, after first strand 
cDNA synthesis  using oligo dT primers, with ampliTaq  DNA poly- 
merase and CD44 primers according  to the protocol provided  with 
the RNA-PCR kit (Perkin-Elmer Corp., Norwalk,  CT). 
The primers were Hu-5'-EcoRV (exon v6) and Hu-3-EcoRV 
(exon v6), corresponding to positions 436-466 and 411-442 of the 
LCLC97 variant region as described by Hofmann et al. (9), and 
5' constant and 3' constant, corresponding positions 513-540 and 
900-922 of the standard CD44 sequence  described  by Stamenkovic 
et al. (14). Amplification  was performed in 30 cycles (30 sec 95~ 
2 min 72~  in a microwave-based  DNA incubator (Ampliwave; 
Kreatech Biotechnology, Amsterdam, The Netherlands).  PCR 
products were analyzed on a 1.5% ethidium bromide-containing 
agarose gel, subsequently transferred to nitrocellulose,  and hybrid- 
ized with a 5' constant CD44-specific probe (9), or an exon v6- 
specific probe labeled with 32p by nick translation. 
Results 
Characterization of  Abs against the Variant Portion of the Human 
CD44 Glycoprotein.  To obtain tools to study the expression 
and function of human variant CD44 glycoproteins, we raised 
polyclonal and monodonal Abs to a fusion protein composed 
of variant exon-encoded sequences v3-vl0 of human CD44 
(Fig.  1,  and Materials and Methods). As we have recently 
shown (12), the polyclonal rabbit antiserum obtained recog- 
nizes fusion proteins encoded by the variant exons v3-vl0 
found in immortalized keratinocytes, as well as fusion pro- 
teins encoded by only exons v3,4 or v6,7 in Western blots, 
and detects CD44 variants on several human epithelia. 
For the generation of mAbs, we also immunized with the 
fusion protein encoded by exons v3-10 of human CD44 (Fig. 
1, and Materials and Methods). To elucidate the exon specificity 
of the mAbs obtained, these mAbs were further tested against 
several bacterial fusion proteins in ELISA (not shown) and 
Western blot analysis (Fig. 2). mAb VFF6 reacted with fu- 
sion protein DII/III (encoded by exons v5,6), but not with 
fusion proteins DI (encoded by v3,4) and DIII (encoded by 
v6,7) (Fig. 2 A); mAbs VFF4 and VFF7 reacted with fusion 
A 
N v/////////////////////l  I  I 




I  I  I  I  I 
v6  v7  v8  v9  vlO 
D1 
C744  v142 
i  :  DII/III 
]  ~v290  v460 
i  ~  :Dill  i  I  i   v638 
vFF6  VFF9i 
VFF11  "  VFF7  " 
899  Koopman  et al. 






Figure  1.  (.4)  Schematical  representation of HPKlI-type 
CD44v. (Open boxes v3-10) Exons  that are expressed in im- 
mortalized keratinocytes  (HPKII), but that are spliced out 
in (hatched  boxes) standard  CD44. (B) Schematical  representa- 
tion of  bacterially  ~pressed  fusion  proteins encoded  by pGEX 
or pATH constructs (see Materials and Methods) CD44v 
HPKII (v3-10), DI, DII/III, and DIlL (C) Location  of the 
epitopes that are recognized  by the mAbs VFF6, VFF7 (and 
VFF4), VFF9, and VFF11. Figure 2.  Western blot analysis 
of CD44v-encoded bacterial fusion 
proteins  with  different  CD44v- 
specific mAbs. (A-D) Replica gels 
(10% polyacrylamide) carrying the 
following order of the fusion pro- 
teins: (lane 1) DI, (lane 2) DII/III, 
and (lane 3) Dill. The figure shows 
staining of the fusion proteins with 
the mAbs (.4) VFF6, (B) VFF7, (C) 
VFFg, and (D) VFFll. (E) Coomas- 
sie brilliant  blue-stained SDS gel is 
shown.  In lanes 1 and 3,  affinity- 
purified fusion proteins were loaded; 
lane 2  shows a crude bacterial ly- 
sate. (M) Size marker. 
proteins DII/III and Dill, but not with DI (Fig. 2 B), and 
mAb VFF9 only recognized fusion protein Dill (Fig. 2 C). 
mAb VFFll only showed reactivity with DI (Fig. 2 D). These 
data indicate that the five mAbs recognize four different epi- 
topes on the variant portion of CD44, which are encoded 
by exons v3 or v4 (VFFll),  v5 or v6 (VFF6),  v6 (VFF4, 
VFF7), and v7 or v8 (VFF9),  respectively. The position of 
these epitopes on the variant portion of CD44 is schemati- 
cally depicted in Fig.  1 C. 
Human  Lymphohematopoietic Cells Express Low Levels of 
Variant CD44.  In contrast to the strong expression of stan- 
dard CD44-encoded epitopes (18), splice variants  of CD44 
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Figure 3.  Human lymphohematopoietic cells  and cell lines express low 
levels of  variant CD44. Binding of  different Abs was measured by FACS  | 
Results show mean fluorescence intensity. Negative controls  (<5 inten- 
sity units in all cases) have been substracted. One single fluorescence peak 
was found in all cases. 
were barely detectable on normal lymphohematopoietic  cells 
and tissues. In tissue sections of tonsils, LNs, thymus, small 
and large intestine (containing mucosa-associated lymphoid 
tissue),  lung, liver, and skin, we observed no unequivocal 
staining of lymphocytes and macrophages, including alveolar 
macrophages and Kupffer's cells, by immunoperoxidase with 
any of the antivariant CD44 Abs. It should be stressed that 
by the same technique, these Abs strongly stained epidermal 
keratinocytes of normal skin, as well as several other epithelia 
(12, and data not shown). 
In FACS  |  analysis, polyclonal Abs against  the complete 
variant region (v3-10),  and mAbs VFF7 (and VFF4,  not 
shown) against v6 weakly stained PBL, tonsillar lymphocytes, 
monocytes, and granulocytes,  as well as the cell lines CEM, 
JVM-2, and U937 (Fig. 3). By contrast, except granulocytes, 
neither of these cells were stained with mAbs against  epi- 
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VFF11 (v3/4) 
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Figure 4.  T cell activation by anti-CD3, PMA, or antigen  leads to tran- 
sient upregulation of CD44 variants containing  the metastasis-associated 
domain coded by exon v6. (PB T) peripheral blood T lymphocytes (nonac- 
tivated); (CD3 T and PMA T) 24 h after activation with CD3 and PMA. 
(K61-20) Influenza-specific T  cell clone. 
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The keratinocyte cell line HaCat, which was used as a posi- 
tive control, stained with all of the antivariant CD44 Abs 
(Fig.  3).  The data indicate that a very small proportion of 
CD44 as expressed on lymphocytes, monocytes, and granu- 
locytes consists of splice variants that contain the metastasis- 
associated  domain encoded by exon v6. 
T  Cell Activation Leads to Transient Upregulation of CD44 
Variants Containing the Metastasis-associated Domain Encoded by 
v6.  The fact that activation greatly influences both the adhe- 
siveness and migratory properties oflymphocytes, prompted 
us to explore whether lymphocyte activation influences ex- 
pression of CD44 splice variants.  We observed that human 
peripheral blood T lymphocytes, upon activation with either 
anti-CD3 mAb and IL-2 or with the phorbol ester PMA, 
strongly upregulate the expression  of variant CD44 glyco- 
protein(s) as detected by polyclonal Ab against CD44v (v3-10) 
(Fig. 4). Also, antigenic contact leads to strong upregulation 
of CD44v (v3-10) on the influenza-specific  T ceU clone K61-20 
(Fig.  4).  It is interesting that analysis of activated lympho- 
cytes using the mAbs against various CD44 variant epitopes, 
gave positivity only with mAbs recognizing an epitope(s) 
encoded by metastasis-associated  exon v6 (Fig. 4). Time ki- 
netic studies showed that the upregulation of variant CD44 
was transient peaking at 24-48 h and returning to background 
levels at day 3 (Fig.  5). Restimulation of the cells at day 6 
led  to  reinduction of variant  CD44  expression  (data  not 
shown). The enhanced expression of variant CD44 as found 
was accompanied  by upregulation of Ib2R (CD25) (data not 
shown), and preceded proliferation as measured by [3H]thy- 
midine incorporation (Fig.  5).  Hence, upon activation by 
phorbol ester, anti-CD3, or specific antigen, T lymphocytes 
show an early transient upregulation of CD44 variants con- 
taining the metastasis-associated  domain encoded by v6. 
PCR Analysis Demonstrates at Least Three v6-containing CD44 
Splice Variants.  To determine the level of regulation of variant 
CD44 expression and to elucidate the structure of the CD44 
splice variants expressed in lymphocytes, RNA prepared from 
resting and activated  T  lymphocytes and several lymphoid 
cell lines was subjected to reverse transcription PCR amplifi- 
cation. In these studies, primers corresponding to sequences 
of the 5' and the 3' standard (constant) region and the v6 
exon region were used. With the 5' and 3' constant primers, 
a major PCR product of"~450 bp was obtained from all cells 
except Jurkat (Fig. 6 A), which is also CD44 negative at the 
protein level (Fig. 3). The size of this product corresponds 
to that expected for the standard CD44 message.  In addi- 
tion, up to three minor bands of *580,  680,  and 860 bp 
were obtained from PBL, activated T lymphocytes, and CEM, 
but not from the CD44 variant negative cell line HSB (Fig. 
6 A). Hybridization with a v6-specific probe shows that all 
of these three splice variants contain v6 (Fig.  6 B).  These 
v6-containing PCR products were relatively most abundant 
at  24  and  48  h  after  T  cell  activation  strongly,  suggest- 
ing that expression of vCD44 is transcriptionally regulated 
(Fig.  6). 
To gain insight into the structure of the CD44 variants, 
i.e., in which exons are flanking v6, we performed PCR anal- 
ysis using v6-specific up- or downstream primers in combi- 
nation with  the  5'  and 3'  constant primers, respectively. 
Priming from v6 upstream yielded one PCR product of"~350 
bp, indicating absence of v3-v5, whereas downstream priming 
yielded up to three major bands migrating at  '~220,  550, 
and 770,  and some minor bands, confirming the presence 
in lymphocytes of at least three splice variants with v6. These 







100  40000 
vCD44 
-- -  3H Thymidine 
30000 
~\\\  E 
10  20000  .CO 
,10000 
1  ￿9  ~  .......  0 
1  2  3  4  5  6  7  8 
days 
Figure 5.  Time kinetics of variant CD44 upregulation (the epitopes 
seen by the polyclonal Ab to v3-10) in relation to [SH]thymidine incor- 
poration.  Similar time kinetics were found for v6 expression. 
Figure 6.  PCR amplification of cDNA with 5' and 3' CD44-specific 
primers. PCR products were transferred to nitrocellulose and hybridized 
with (A) CD44-specific 5' probe, and (B) probe specific  for CD44 variant 
exon v6.  The probes were labeled with s2p by nick translation. 
901  Koopman et al. Table  1.  Expression of CD44 Variants in Non-Hodgkin's 
L  ymphomas 
Grade* 
Antibody specificity 
(No.  positives) 
n v3-10v3/4v5/6  v6  v7/8 
Low-grade 
Diffuse small cell  7  0  0  0  0  0 
Follicular  5  0  0  0  0  0 
Intermediate/High grade 
Diffuse large cell  14  7  0  0  6  0 
Immunoblastic  5  3  0  0  2  0 
Anaplastic (Ki-1)  5  4  0  0  2  0 
* According to the WF (20). 
downstream variant exons (v6-10), and v6 with an incom- 
plete set  of downstream variant exon (550). 
Overexpression of CD44  Variants Containing the Metastasis 
Domain v6 in Aggressive Non-Hodgkin's Lymphomas.  Prior 
studies have related expression  of CD44  on NHLs to dis- 
semination and to aggressive tumor behavior (3-5). At this 
time, a putative heterogeneity of CD44 molecules could not 
be assayed. This earlier finding, and the now recognized role 
of larger variants of CD44 in lymphogenic tumor spread (8), 
together with the present data showing that lymphocytes 
upregulate v6 upon activation, prompted us to pursue the 
possibility that NHLs express CD44 variants.  Indeed, of a 
group of 36 NHLs selected for moderate to high expression 
of standard CD44 as detected by mAb NKI-P1, 14 tumors 
were found to express CD44 variant glycoproteins (Table 1). 
It is interesting that all of these vCD44 + lymphomas be- 
longed to the intermediate- and high-grade categories of the 
WF (20),  which are characterized by aggressive clinical be- 
havior and are therefore also termed "aggressive" lymphomas 
(23). In contrast, none of the low-grade NHLs expressed im- 
munohistochemically detectable levels of CD44 variants.  In 
view of the absence of immunohistochemicaUy detectable levels 
of CD44 variants in normal lymphoid tissues, these findings 
indicate a marked overexpression in the positive tumors. The 
level of variant expression in those tumors was variable ranging 
from weak to strong. 10 of 14 CD44 variant positive tumors 
showed expression  of v6-encoded epitopes (Table 1 and Fig. 
7).  Three tumors that stained weakly with the polyclonal 
antiserum did not react  with any of the mAbs. Hence,  10 
of 24 CD44 § aggressive lymphomas overexpress CD44 vari- 
ants containing the metastasis  associated  domain v6. 
Discussion 
Lymphohematopoietic cells have been known to express 
the standard, so-caUed  hematopoietic (14) form of  CD44, that 
Figure 7.  Expression  of the metastasis-associated  variant of CD44 on aggressive  human  NHLs. (A) High-grade  (anaplastic)  B cell lymphoma  stained 
with mAb VFF7  against  v6. Note that preexisting  nonneoplastic  lymphocytes  in this LN show  no detectable  staining.  (B) High-grade  T cell  lymphoma 
infiltrating into the muscularis propria of the bowel wall, stained  with mAb VFF7 (V6). (x 125). 
902  CD44  Variants on Lymphocytes has been implicated in facilitating lymphocyte migration from 
the blood into lymphoid tissues (24, 25). After antigenic stim- 
ulation in vivo,  rat lymphocytes have recently been shown 
to synthesize one specific variant of CD44 carrying the v6 
exon (11). By using Abs raised against the variant portion 
of the human CD44 protein, we now demonstrate that human 
leukocytes express low levels of CD44 splice variants and that 
human T  lymphocytes, can be stimulated in vitro to tran- 
siently upregulate expression of variant epitopes. These vari- 
ants, which contain sequences that in the rat confer metastatic 
behavior to carcinoma and sarcoma cells (8), are overexpressed 
in about half of the studied aggressive NHLs. 
Whereas biochemical studies indicated the presence of het- 
erogenous sets  of CD44  glycoproteins on many cell types 
including lymphohematopoietic cells (18, 26, 27),  and sev- 
eral CD44 RNA splice variants have recently been identified 
(8, 9, 12, 14, 28-31) our present study documents regulated 
differential expression at the protein level of variant domains 
in lymphohematopoietic cells. These variants are expressed 
at very low levels on normal resting lymphocytes, granulo- 
cytes and monocytes, and on several lymphohematopoietic 
cell lines (Fig. 3), in contrast to the abundant expression of 
standard CD44 on those cells (Fig. 3). However, T cell acti- 
vation either by anti-CD3 mAb, phorbol ester PMA, or specific 
antigen, leads  to a transient upregulation of variant CD44 
glycoproteins (Fig. 4), which peaks at 24 h and precedes blast 
transformation and S phase (Fig.  5). A similar upregulation 
of CD44 splice variants can be found upon activation of B 
lymphocytes (Griffioen, A., manuscript in preparation).  These 
data are compatible with our previous observations in rats 
that showed CD44 variant expression upon in vivo stimula- 
tion by antigen (11). 
It is interesting that among the CD44 variant glycopro- 
teins expressed by activated T lymphocytes, those containing 
the metastasis-associated exon v6, predominate (Figs. 3 and 
4).  PCR analysis of the variant transcripts revealed regula- 
tion  of variant  expression at  the transcriptional  level and 
demonstrated the existence of at least three transcripts con- 
taining v6, consisting of either v6 alone or v6 in combina- 
tion with several or all downstream exons v7-10 (Fig. 6). 
In the rat, only one v6 + PCR product has been detected in 
lymphocytes sorted for the epitope (11). This discrepancy might 
reflect interspecies differences or might be caused by different 
modes of stimulation. Of the v6-containing transcripts, only 
the longest transcript has been described previously (9), but 
in this study, no lymphoid cells were included. It remains 
to be determined whether the other variants are specific for 
lymphocytes. In the rat, variants containing v6 are part of 
the process of metastasis formation (8).  Hence, at an early 
stage of activation, T lymphocytes acquire molecules which 
in another setting can promote tumor metastasis. 
The insertion of exon-encoded sequences into the mem- 
brane-proximal region of CD44 on activated T lymphocytes 
may serve a number of different functions. For example, spliced 
exons could modulate the ligand-binding properties of CD44. 
Indeed, it has been shown by Aruffo et al. (32) that the pres- 
ence of a 135-amino acid insert within the membrane-proximal 
region, as found in the so-called epithelial variant of CD44 
(corresponding  to  v8-10  in  Fig.  1)  dramatically reduces 
hyaluronic acid binding, and lymphocyte adhesion to cultured 
high endothelial venules (25). Binding of CD44 to its other 
putative ECM ligands collagen (33) and fibronectin (34) might 
be modulated in a similar way. Alternatively, the introduc- 
tion of new sequences into the CD44 molecule might create 
entirely new binding specificities. In this way, CD44 might 
contribute to the structural basis of tissue-specific  homing. 
We observed that a significant proportion  of aggressive 
NHLs overexpress CD44 variants that carry the metastasis- 
associated  exon v6 (Table  1, Fig. 7).  Unlike the low-grade 
lymphomas, which have preserved more functions of.their 
nonneoplastic counterparts such as homing pattern, and re- 
sponsiveness to immunoregulation, and usually follow an in- 
dolent clinical course, many lymphomas of the intermediate 
and high-grade categories of the WF (20) have an aggressive 
natural history. They are autonomous neoplasms showing 
destructive growth and behaving in a fashion similar to that 
of other highly malignant nonlymphoid tumors (20,  23). 
Whereas standard CD44 is expressed on most lymphocytes 
and lymphomas and may have a role in homing to lymphoid 
tissues, activated lymphocytes and aggressive lymphomas pro- 
duce v6 variants. They share infiltrative,  adhesive, and migra- 
tory properties. It is likely that v6 has a role in this aggres- 
sive behavior by either recruiting new molecular partners, 
by changing CD44 properties, and/or by pleiotropic actions 
(growth  advantage and  induction  of an  array of relevant 
functions). 
We thank A. J. Tigges and R. M. J. Keehnen for technical assistance; Dr. C. G. Figdor for mAb NKI-P1; 
Dr. K. C.  Kuypers for clone K61-20; and Dr. M. Snoek for critical reading of the manuscript. 
This work was supported by grants He 551-6-1 of the Deutsche Forschungsgemeinschaft and IKA-91/9 
of the Dutch Cancer Society. 
Address correspondence to S. T. Pals, Department of Pathology H2, Academic Medical Center, University 
of Amsterdam, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands. 
Received for publication 15 October 1992 and in revised  form 14 December 1992. 
References 
1.  Nicolson, G.L. 1987. Tumor cell instability, diversification,  and 
progression to the metastatic phenotype: from oncogene to 
oncofetal expression. Cancer Res. 47:1473. 
2.  Hart, I.IL., N.T. Goode, and R..E. Wilson.  1989. Molecular 
903  Koopman  et al. aspects of the metastatic cascade. Biochim. Biophys. Act,,. 989:65. 
3.  Pals, S.T., E. Horst, G.J. Ossekoppele, C.G. Figdor, gJ. Scheper, 
and CJ.L.M. Meijer. 1989. Expression of lymphocyte homing 
receptor (CD44)  as a mechanism of dissemination  in  non- 
Hodgkin's lymphoma. Blood. 73:885. 
4.  Horst, E., C.J.L.M. Meijer, T. Radaszkiewicz, G.J. Ossekop- 
pele, J.HJ.M. van Krieken, and S.T. Pals. 1990. Adhesion mol- 
ecules in the prognosis of diffuse large-cell lymphoma: expres- 
sion  of  a  lymphocyte  homing  receptor  (CD44),  LFA-1 
(CD11a/CD18),  and ICAM-1 (CD54). Leukemia (Baltimore). 
4:595. 
5. Jalkanen, S., H. Joensuu, and P. Klemi. 1990. Prognostic value 
of lymphocyte homing receptor and S value in non-Hodgkin's 
lymphoma. Blood. 75:1549. 
6.  Sy, M.S., Y.I. Guo, and I. Stamenkovic.  1991. Distinct effects 
of two CD44 isoforms on tumor growth in vivo.J. Extx Med. 
174:859. 
7.  Birch, M., S. Mitchell, and I. Hart. 1991. Isolation and char- 
acterization of human melanoma variants expressing high and 
low levels of CD44.  Cancer Res. 51:6660. 
8.  Gtinthert, U., M. Hofmann, W. Rudy, S. Reber, M. Z611er, 
I. Haufmann, S. Matzku, A. Wenzel, H. Ponta, and P. Herr- 
lich.  1991.  A  new  variant  of glycoprotein CD44  confers 
metastatic potential to rat carcinoma cells. Cell. 65:13. 
9.  Hofmann, M., W. tLudy, M. Z611er, C. T61g, H. Ponta, P. 
Herrlich, and U. Giinthert. 1991. CD44 splice variants confer 
metastatic behavior in rats: homologous sequences are expressed 
in human tumor cell lines.  Cancer Res. 51:5292. 
10.  Reber, S., S. Matzku, U. Giinthert, H. Ponta, and M. Z611er. 
1990. Retardation of metastatic growth after immunization 
with metastasis-specific monoclonal antibodies.  Int. J. Cancer. 
46:919. 
11.  Arch, R., K. Wirth, M. Hofmann, H. Ponta, S. Matzku, P. 
Herrlich, and M. Zoller. 1992. Participation in normal immune 
responses of a metastasis inducing splice variant of CD44. Science 
(Wash. DC).  257:682. 
12.  Heider, K.H., M. Hofmann, E. Horst, F. van den Berg, H. 
Ponta, P. Herrlich, and S.T. Pals. 1993. A human homologue 
of the rat metastasis-associated  variant of CD44 is expressed 
in colorectal carcinomas and adenomatous polyps. J. Cell Biol. 
120:227. 
13.  Smith, D.B., and K.S. Johnson. 1988. Single-step purification 
of polypeptides expressed  in Escherichia coli as fusions  with 
glutathione S-transferase.  Gene (Amst.).  67:31. 
14.  Stamenkovic, I., M. Amiot, J.M. Pesando, and B. Seed. 1989. 
A lymphocyte molecule implicated in lymph node homing is 
a member of the cartilage link protein family. Cell. 56:1057. 
15.  Angel, P., E.A. Allegretto, S.T. Okuio, K. Hatton, W.J. Boyle, 
T.  Hunter,  and M.  Karin.  1988. Oncogene jun  encodes a 
sequence-specific trans-activator similar to AP-1. Nature (Lond.). 
332:166. 
16.  K6hler, G., and C. Milstein. 1975. Continuous culture of fused 
cells secreting antibody of predefined specificity. Nature (Lend.). 
265:495. 
17.  Kearney, J.F., A. Radbruch, B. Liesegang,  and K. Rajewski. 
1979. A new mouse myeloma cell line that has lost immuno- 
globulin expression but permits the construction of antibody- 
secreting hybrid cell lines, j.  lmmunol.  123:1548. 
18.  Pals, S.T., F. Hogervorst, G.D. Keizer, T. Thepen, E. Horst, 
and C.C. Figdor.  1989. Identification of a widely distributed 
90-kDa glycoprotein that is homologous to the hermes-1 human 
lymphocyte homing receptor. J. lmmunol.  143:851. 
19.  Laemmli, U. 1979. Cleavage of structural proteins during the 
assembly  of the  head  of bacteriophage T4.  Nature  (Lond.). 
227:680. 
20.  The non-Hodgkin's lymphoma classification project: National 
Cancer  Institute  sponsored  study  of classification  of non- 
Hodgkin's lymphomas. Summary and description of a working 
formulation for clinical usage.  1982. Cancer (Phila.). 49:2112. 
21.  Koopman, G., Y. van Kooyk, M. de Graaff, C.J.L.M. Meyer, 
C.G. Figdor, and S.T. Pals. 1990. Triggering of the CD44 an- 
tigen on T lymphocytes promotes T cell adhesion through the 
LFA-1 pathway. J. Immunol.  145:3589. 
22.  Kuyper, K.C., P. Treep-van Leeuwen, F. Miedema, and C.J. 
Lucas. 1991. AUo-cross-reactivity  of a neuraminidase-specific 
human T-cell clone dependent on presentation of an endoge- 
nous B-cell-specific antigen. Eur. j.  lmmunol.  21:1453. 
23.  Cohen,  P.J.,  and  E.  Jaffe.  1990. Histopathology  and  im- 
munophenotyping of non-Hogkin's lymphoma. In The Non- 
Hodgkin's Lymphomas. I.T. Magrath,  editor. Williams  and 
Wilkins,  Baltimore. 49-76. 
24. Jalkanen, S., R.F. Bargatze, J. De Los Toyos, and E.C. Butcher. 
1986. A lymphocyte cell surface glycoprotein involved in en- 
dothelial cell recognition and lymphocyte homing. Eur.J. Im- 
munol.  16:1195. 
25.  Stamenkovic, I., A. Aruffo, M. Amiot, and B. Seed. 1991. The 
hematopoietic and epithelial forms of CD44 are distinct poly- 
peptides with different adhesion  potentials for hyaluronate- 
bearing cells. EMBO (Eur. Mol. Biol. Organ.)J.  10:343. 
26. Jalkanen,  S., M. Jalkanen,  R. Bargatze,  M. Tammi, and E.C. 
Butcher. 1988. Biochemical properties of glycoproteins involved 
in lymphocyte recognition of high endothelial venules in man. 
J. Immunol.  141:1615. 
27.  Picker, L.J., M. Nakache, and E.C. Butcher. 1989. Monoclonal 
antibodies to human lymphocyte homing receptors define  a 
novel class of adhesion  molecules in diverse cell types. J. Cell 
Biol.  109:927. 
28.  Dougherty, G.J., P.M. Lansdorp, D.L. Cooper, and R.K. Hum- 
phries.  1991. Molecular cloning of CD44R1 and CD44R2. 
Two novel isoforms of the human CD44 lymphocyte homing 
receptor expressed by hematopoietic cells.J. Extx Med. 174:1. 
29.  Brown, T.A., T. Bouchard, T. St. John, E. Wayner, and W.G. 
Carter. 1991. Human kerotinocytes express a new CD44 core 
protein (CD44E) as a heparansulfate  intrinsic membrane pro- 
teoglycan with additional exons. J.  Cell Biol. 113:207. 
30.  Shtivelman, E., and M. Bishop.  1991. Expression  of CD44 is 
repressed  in neuroblastoma cells. Mol.  Cell. Biol. 11:5446. 
31. Jackson, D.G., J. Buckle,/, and J.I. Bell. 1992. Multiple vari- 
ants of the human lymphocyte homing receptor CD44 gener- 
ated by insertion at a single site in the extracellular  domain. 
J. Biol. Chem.  267:4732. 
32.  Aruffo, A., I. Stamenkovic, M. Melnick, C.B. Underhill, and 
B. Seed. 1990. CD44 is the principle cell surface receptor for 
hyaluronate. Cell. 61:1303. 
33.  Carter, W.G., and E.A. Wayner. 1988. Characterization of the 
class III collagen receptor, a phosphorylated, transmembrane 
glycoprotein expressed in nucleated human cells.J. Biol. Chem. 
263:4193. 
34. Jalkanen, S., and M. Jalkanen.  1992. Lymphocyte CD44 binds 
the COOH-terminal heparin-binding domain of fibronectin. 
j.  Cell Biol. 116:817. 
904  CD44 Variants on Lymphocytes 